This message was sent to ##Email##
|
|
|
|
|
| |
| HEALTH CARE NEWS AND UPDATES |
Medical Xpress
To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy approaches to kill cancer cells, including the CAR T cell therapy currently attracting broad public attention. "The problem is that CD8 T cells are often exhausted in cancer and chronic infections like HIV, so they die off or stop functioning properly," said Shomyseh Sanjabi, PhD, an assistant investigator at the Gladstone Institutes who has been studying this cell type for nearly 15 years. "I've been trying to better understand how these cells develop in order to find ways to help them regain their function and live longer."
READ MORE
OncLive
There are currently 10 FDA-approved treatments in the multiple myeloma space; however, a more personalized therapy could be key to finding a cure, said Nikhil C. Munshi, MD.
“In five years, we could be bold enough to say, ‘We have cured myeloma,’” said Munshi. “Combining all the drugs we have and what we know about CAR T-cell therapy can do this and be a surrogate for cure.”
READ MORE
|
Promoted by
|
|
|
|
 |
Medical News Today
The uncovering of the molecular acrobatics of a key cell enzyme could lead to new treatments for cancer and metabolic diseases such as obesity and diabetes. The cell enzyme is called PI3KC2A, and though scientists knew that it controlled many crucial cell functions, they remained unsure of the detailed structural mechanisms.
One thing they did know was that the enzyme controls what occurs at cell membranes when they receive external signals.
READ MORE
WhatIsEpigenetics.com
Throughout our lives, all cells in our bodies experience a normal life cycle of growth, maturity and death. During this time, our cells normally experience damage to DNA by normal functions of the metabolism or exposure to certain environmental factors like UV light. Ordinarily, our body is able to repair the damage done to the DNA in order to restore healthy cell function.
READ MORE
 |
|
Our ihcDirect® method yields a revolutionary technology that opens a spectrum of new clinical applications including intraoperative surgery. Using the Novodiax PolyHRP technology, Intraoperative IHC tests can now be completed in just 10 minutes using fresh frozen tissues.
For more details, see our
 ihcDirect® product list.
|
|
Laboratory Equipment
Negative results and findings in science are perhaps less newsworthy, but they are no less important. Particularly when, as in this case, they demonstrate that a possible new therapeutic pathway against idiopathic pulmonary fibrosis and other diseases associated to short telomeres is in fact safe. Researchers from the Spanish National Cancer Research Centre have shown in a new study that the gene therapy with telomerase that they have developed, and that has proven to be effective in mice against diseases caused by excessive telomere shortening and aging, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.
READ MORE
ScienceDaily
Lung cancer results from effects of smoking along with multiple genetic components. A new study identifies two main pathways for the role of chromosome 15q25.1 — a leader in increasing susceptibility to lung cancer — in modifying disease risk. One pathway is implicated in nicotine dependence. The other plays a part in biological processes such as nutrient transfer and immune system function. The findings increase our understanding of lung cancer cause and development.
READ MORE
|
Promoted by
|
|
|
|
 |
Medical News Today
A new study has identified a way to interfere with cancer cells and prevent them from metastasizing. The key lies in shutting down the cell's ability to take out the trash. One of the most challenging aspects of cancer is its ability to metastasize.
Cancer cells can break away from their current position, travel through the body, and begin multiplying in new, distant locations.
READ MORE
HealthPayerIntelligence
Designing meaningful and high-quality cancer care benefits is a challenge for employer-sponsored health plans.
Cancer, a costly and complex condition that takes many different forms, requires coordination across the entire health care continuum. Developing communication tools and financial support for plan members as they navigate their cancer care can help to improve outcomes and reduce anxiety for employees at a critical juncture in their healthcare journey.
READ MORE
 |
|
Donate now to help Doctors Without Borders bring emergency medical care where it is needed most. Doctors Without Borders USA relies on unrestricted donations from private donors so when an emergency strikes we assess the needs and can act fast.
Donate today.
|
|
Cancer Thearpy Advisor
Rates of both melanoma and nonmelanoma skin cancer are increasing globally, and the number of annual skin cancer diagnoses in the United States now exceeds that of all other cancers combined.
Although melanoma was previously most common among older adults, it is currently the second most common cancer affecting individuals age 15 to 29 years and the most common cancer in the 25 to 29 age group.
READ MORE
Cure
The PARP inhibitor talazoparib reduced the risk for disease progression or death by 46 percent compared with chemotherapy in patients with germline BRCA mutation–positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, according to study results published in the New England Journal of Medicine.
In addition, patient-reported quality-of-life measures revealed a prolonged time to deterioration of overall health (24.3 months vs. 6.3 months).
READ MORE
 |
|
At the Association of Community Cancer Centers (ACCC) 35th National Oncology Conference in Phoenix, you’ll experience multidisciplinary strategies and groundbreaking processes to streamline operations, successfully engage patients, maximize staff productivity, improve clinician wellness, and more! Register by August 20
to save up to $125 off registration rates.
|
|
Healio
Active duty military members and veterans in the United States appear to be at elevated risk for melanoma and nonmelanoma skin cancers, according to study results published in Journal of the American Academy of Dermatology.
Although the link between occupational sun exposure and skin cancer is well established, the risks among military personnel required further investigation, according to Jennifer Powers, MD, associate professor of dermatology at the University of Iowa, and colleagues.
READ MORE
| ACS CANCER PROGRAMS UPDATES |
| 2018 Commission on Cancer Paper Competition winners
|
    |
Abstracts were submitted by residents and fellows-in-training that cover topics specific to oncology and directly relates to the CoC mission. After careful review and scoring, we are pleased to announce our first, second and third place winners.
1st Place
Helmi Khadra MD
Tulane University School of Medicine
New Orleans, LA
Re-examining the Incidence of GI Malignancy among Solid Organ Transplant Recipients
2nd Place
Carla Zeballos Torrez, MD
University of Texas Health Science Center
San Antonio, TX
The Role of Six Transmembrane Epithelial Antigen of the Prostate 2 in Hepatocellular Carcinoma
3rd Place
Max Seaton, MD
University of Maryland Medical Center
Baltimore, MD
Chemotherapy VS Checmoradiation After Distal Pancreatectomy: A Study of the National Cancer Database
NCDB
Over the years, the Commission on Cancer (CoC) has received valuable feedback to improve the data collected by the National Cancer Database (NCDB), which directly impacts the patients we all serve. The CoC acknowledges the magnitude of the 2018 changes, which seem overwhelming especially with the unexpected delay in the release of the tools and references that facilitate the task of abstraction including the Standards for Oncology Registry Entry (STORE) effective for cases diagnosed Jan. 1, 2018 and later. The CoC recognizes the challenges faced by our dedicated hospital registrars who continue to work tirelessly to ensure timeliness and accuracy of recording data; however, it is also part of the CoC’s commitment to provide clear and up-to-date instructions based on the collaborative effort of the experts involved in the development of the STORE. While all suggestions could not be implemented immediately with the current version of the STORE, significant changes have been made. For any other questions or concerns, please contact the NCDB at ncdb@facs.org.
The NCDB would not exist without the efforts of cancer registrars across the nation, and the CoC thanks the registrars at all CoC-accredited programs for their perseverance and patience during these difficult, but necessary, times of change.
READ MORE
YouTube
This short film is based on a detailed article written by one of ACS CoC Member Organization representatives Dr. Ernie Bodai and his colleagues about the influence of lifestyle on cancer. The article was published in The Permanente Journal Magazine in 2018.
Watch film here.
ACS
The 2018 Cancer Programs Annual Conference is rapidly approaching!
This conference addresses issues that impact you and your staff in the delivery of high-quality, multidisciplinary, patient-centered care. Throughout the conference there will be a plethora of plenary sessions, breakout sessions and networking opportunities!
Highlights include:
Introductory remarks by David P. Winchester, MD, FACS, and a preview of "What's on the Horizon for Cancer Programs?"
Leadership: How to Take People Where They Don't Necessarily Want to Go but Ought to Be
Importance of Patient-Centered Care: Focus on Navigation and Survivorship
AJCC Staging Manual: Changes to the Breast Chapter
Streamlining Accreditation Operations to Improve Efficiency
Register today to ensure your spot and save money by securing early-bird pricing before Aug. 29! For more information, visit the Cancer Programs Annual Conference website.
The hotel deadline has been extended once again! Book your hotel room by Tuesday, Aug. 28 at 2 p.m. CT to secure the discounted conference rate of $159 + tax.
If you decide last minute to attend, onsite registration will be available. Onsite pricing starting on Aug. 30.
READ MORE
Clinical Research Program
As mentioned in prior communications, the 2018 DCIS Special Study opened July 16. We invite you to visit the 2018 Special Study on DCIS SharePoint site, which will house all materials you will need to participate in the study. We have created a universal login for this site; please note it is case sensitive:
Login: DCISStudy
Password: study2018.
All registrars and co-registrars will be able to access and download materials via the SharePoint site.
READ MORE
ACS
NAACCR is hosting a free webinar covering an update on the 2018 Implementation and Review of the Solid Tumor Rules from 2-3:30 p.m. ET, Aug. 30. One week prior to the live webinar, NAACCR will post case scenarios that will be discussed.
Register here. No CE hours will be associated with this webinar. A recording will be posted to the NAACCR 2018 Implementation page.
READ MORE
American College of Surgeons - NAPRC
The National Accreditation Program for Rectal Cancer (NAPRC) is now accepting applications. The NAPRC was developed to ensure that rectal cancer patients receive appropriate care following a multidisciplinary approach. Programs will be evaluated on the standards and metrics outlined in The National Accreditation Program for Rectal Cancer Standards Manual 2017 (revised October 2017).
READ MORE
ACS
If you have a managerial background you'll be interested in the latest position opening within the Cancer Programs at The American College of Surgeons (ACS). This manager role is for the National Cancer Database Information and Data Standards (NCDB).
Do you have experience with:
- Managing a team
- CTR
- The NCDB Standards for Oncology Registry Entry (STORE) coding manual
- Managing agile data collection
This exciting position is located in the ACS Chicago office. In this role you will manage the NCDB data quality by evaluating quality of existing and incoming data, recommending changes in data collection procedures and registrar training, working with outside organizations to assure quality and continuity of data requirements and assisting with Cancer Programs training activities.
If you have incredible interpersonal skills, function well with multiple projects and tight deadlines, have a high level of energy and have a CTR certification we want you to apply!
To review this career opportunity in full detail and to apply click here.
ACS
The AJCC Cancer Staging Manual is the gold standard to help the cancer patient management team determine the correct stage for patients, allowing for the most appropriate care plan.
The AJCC Cancer Staging Manual is used by physicians and health care professionals throughout the world to facilitate the uniform description and reporting of neoplastic diseases. Proper classification and staging of cancer is essential for the physician to assign proper treatment, evaluate results of management and clinical trials, and to serve as the standard for local, regional and international reporting on cancer incidence and outcome.
This corrected third printing includes the following features:
- Revised breast cancer staging system
- Revised histology codes in each chapter
- Corrected errata posted on www.cancerstaging.org through Feb. 2.
Special 25 percent discount! Expires Dec. 31.
Click here for the Springer order form.
READ MORE
| IMPORTANT DATES AND DEADLINES |
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
®: Cancer Data at Your Fingertips
